Form D · Pharmaceuticals
TrialSpark, Inc.
New York, NY · CIK 0002028122
Offering snapshot reported Jul 2, 2024 · SEC filing
- Reported sold
- $372M Offering amount: $512M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 21, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 2, 2024 | Initial | $372,249,945 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-517677
Source: Form D, filed Jul 2, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Scott Kupor | Director |
| Alfred Lin | Director |
| Benjamine Liu | Director, Executive |
| Michael Moritz | Director |
| Linhao Zhang | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
16 E 34 Th St Fl 10
New York, NY, 10016-4411
New York, NY, 10016-4411